Pharvaris (NASDAQ:PHVS) Shares Up 5.3% – Here’s Why

Pharvaris (NASDAQ:PHVS)’s stock price rose 5.3% on Tuesday . The company traded as high as $19.84 and last traded at $19.34. Approximately 6,321 shares were traded during trading, a decline of 86% from the average daily volume of 46,693 shares. The stock had previously closed at $18.36.

Pharvaris Price Performance

The firm’s 50 day moving average price is $19.42 and its two-hundred day moving average price is $19.33. The stock has a market cap of $1.01 billion, a PE ratio of -6.91 and a beta of -3.06.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pharvaris in the third quarter valued at about $906,000. State Street Corp purchased a new stake in Pharvaris in the 3rd quarter worth approximately $1,000,000. Geode Capital Management LLC increased its position in Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after purchasing an additional 5,753 shares during the period. Finally, Novo Holdings A S grew its stake in shares of Pharvaris by 47.7% in the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.